SAN DIEGO , Aug. 09, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that two abstracts for the company’s lead therapeutic candidate, ATYR1923,

Management to host conference call and webcast on August 10th at 5:00 pm EDT / 2:00 pm PDT SAN DIEGO , Aug. 03, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways,

SAN DIEGO , July 29, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that the U.S. Patent and Trademark Office (USPTO) has granted a patent

Results from proof-of-concept study are expected in September 2021 . SAN DIEGO , July 08, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that

Event will feature Dr. Daniel Culver , Director of the Interstitial Lung Disease Program at the Cleveland Clinic . Conference call and webcast scheduled for Tuesday June 29 th at 5:00pm ET / 2:00pm PT . SAN DIEGO , June 23, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc.

  Preclinical candidate is second to demonstrate selective blocking ability from in-house panel of antibodies targeting NRP2. aNRP2-14 blocks Semaphorin 3F/NRP2 signaling pathways which are implicated in immune-mediated diseases. SAN DIEGO , June 10, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc.

SAN DIEGO , May 25, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced the appointment of Sara Zaknoen , M.D., to the company’s Board of Directors.

Findings advance understanding of mechanistic impact of blocking NRP2/VEGF signaling axis with ATYR2810 on aggressive tumor cells SAN DIEGO , May 19, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines

Data from Phase 1b/2a clinical trial of ATYR1923 in pulmonary sarcoidosis expected in the third quarter. Preclinical data for IND candidate ATYR2810 showed anti-tumor effects in models of TNBC and NSCLC. Bispecific antibody project with subsidiary Pangu BioPharma achieved milestones for first of

Two-year grant awarded by the Hong Kong Government’s Innovation and Technology Commission is funding the development of new bispecific antibodies targeting NRP2 SAN DIEGO , May 12, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and